

November 7, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of publication of the research articles in collaboration with Hamamatsu University School of Medicine

- Proof of concept of the potential therapeutic application of next generation SHED for brain cancer - (excerpt from Japanese version)

Tokyo, November 7, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that the research articles were published in collaboration with Department of Neurosurgery, Hamamatsu University School of Medicine regarding the innovative research results with the next generation SHED (stem cells from human exfoliated deciduous teeth) in preclinical models of brain cancer.

Key points

- Confirmed the migratory ability of SHED for glioma cells and lung cancer cells.
- Combined administration of the SHED engineered to express an enzyme, thymidine kinase, and ganciclovir that would be converted into a toxicant for tumors by thymidine kinase demonstrated robust antitumor effects in a mouse glioma model.
- This engineered SHED was able to effectively treat a mouse model of lung cancer brain metastases as well.
- This new cell therapy method should be a promising therapeutic approach for the brain tumors and metastatic brain cancer.

Publication:

1. Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth. Horikawa M, Koizumi S, Oishi T, Yamamoto T, Ikeno M, Ito M, Yamasaki T, Amano S, Sameshima T, Mitani Y, Otani Y, Yan Y, Suzuki T, Namba H, Kurozumi K. *Cancer Gene Ther.* 2022 Sep 8. doi: 10.1038/s41417-022-00527-5.
2. Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases. Oishi T, Ito M, Koizumi S, Horikawa M, Yamamoto T, Yamagishi S, Yamasaki T, Sameshima T, Suzuki T, Sugimura H, Namba H, Kurozumi K. *Mol Ther Methods Clin Dev.* 2022 Jul 6;26:253-265. doi: 10.1016/j.omtm.2022.07.001.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com